TY - JOUR
AU - Perry, Rachel J
AB - Endocrinology, 2023, 164, 1–2 https://doi.org/10.1210/endocr/bqad036 Advance access publication 21 February 2023 Commentary Rachel J. Perry Departments of Internal Medicine (Endocrinology) and Cellular & Molecular Physiology, Yale School of Medicine, New Haven, CT 06520, USA Correspondence: Rachel J. Perry, PhD, PO Box 208026, SHM BE36-B New Haven, CT 06520-8026, USA. Email: rachel.perry@yale.edu. Key Words: aspirin, hepatic glucose production, phospholipase c, inositol 3-triphosphate Abbreviations: COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug. In a recent edition of Endocrinology (1), Dai and colleagues Although this was a single report and has not been validated report a new metabolic action of aspirin. They demonstrate in larger studies, these data suggest that there may be a mech- that, through the cyclooxygenase (COX)/TXA2/thromb- anism beyond an effect of NSAIDs to inhibit gluconeogenesis: oxane A2 receptor axis, aspirin reduces gluconeogenic gene it is rare to observe hypoglycemia as the result of simple sup- expression and inhibits glucagon action through suppression pression of hepatic glucose production without an additional of phospholipase C/inositol 3-triphosphate signaling, thereby contribution from inappropriate hyperinsulinemia. reducing hepatic glucose production. These data follow up on Taken together, Dai and colleagues’ data highlight an oppor- previously unexplained observations first made decades ago: tunity for further therapeutic development 
TI - It's Not Just for Pain: A New Metabolic Function of Aspirin
JF - Endocrinology
DO - 10.1210/endocr/bqad036
DA - 2023-02-21
UR - https://www.deepdyve.com/lp/oxford-university-press/it-s-not-just-for-pain-a-new-metabolic-function-of-aspirin-3tnyqPfCBd
VL - 164
IS - 4
DP - DeepDyve
ER -